Today, notice of the third extension of the “final” DESI notice appeared on the Federal Register pre-publication page here. The first “final” notice (which was published in May 2026) “concluded that all outstanding hearing requests for estrogen-androgen fixed-combination drug products under Docket FDA-1998-P-0083 had been withdrawn, and that such products lack substantial evidence of effectiveness for the treatment of moderate to severe vasomotor symptoms associated with the menopause in patients not improved by estrogen alone”. That notice stated that shipment on any product not covered by an approved NDA or ANDA would be unlawful as of June 26, 2026.

“FDA subsequently extended the effective date of the May 2026 Notice to September 24, 2026, and then to November 4, 2026, to allow the Agency sufficient time to consider issues raised by interested parties following publication of the May 2026 Notice” (see previous Lachman Blog post here). The current notice indicates that FDA needs more time to consider the issues raised by stakeholders and it thus extended the effective date of the final notice another 6 months from November 4, 2026, to May 4, 2027.

DESI, as readers of this blog likely know, is an acronym for Drug Efficacy Study Implementation, a program that looked at the efficacy of drugs that were initially approved on the sole basis of safety prior to the implementation of the efficacy requirement imposed by the Kefauver–Harris Amendments of 1962. The DESI program is now about 64 years old and is still being cleaned up and finalized. These estrogen-androgen fixed-combination drug products are not the only outliers and remember the action on these products began in earnest in 1998. The process can be long and tedious with hearings, review of studies and additional information. Don’t forget the evolution of medical treatment may change over these long delays.  However, it looks like this final, final, final, final action may be concluding soon. Given the lengthy timelines for making many of these DESI decisions, the acronym should stand for Don’t Expect Solutions Imminently!